Singapore
Pierce Chow is Professor at the DukeNUS Medical School and Surgical Director of the Comprehensive Liver Cancer Clinic at the National Cancer Center Singapore. He is concurrently Senior Consultant Surgeon in HPB and Transplant Surgery at the Singapore General Hospital, NMRC Senior Clinician Scientist and Adjunct Faculty at the Genome Institute of Singapore. Pierce has leveraged on his extensive clinical experience and on his Asia-Pacific professional contacts to successfully lead multi-national investigator-initiated clinical trials. In 2012, he was conferred the NMRC National Outstanding Clinician Scientist Award in recognition of his work on Liver Cancer. In 2016 he was awarded the NMRC TCR grant for a Flagship Program in Liver Cancer. SKILLS AND ACHIEVEMENTS Multi-center clinical trials Co-founded the Asia-Pacific Hepatocellular Carcinoma (AHCC) Trials Group in 1997 and has been protocol chair of 5 multi-center trials that has enrolled more than 1000 patients from 30 centers in 14 countries in the Asia-Pacific. In 2016 he closed a phase III trial comparing sorafenib with a brachytherapy device SirSphere® for liver cancer that enrolled 360 patients from 27 centers on 12 countries. Medical Devices Conceptualized and lead the multi-disciplinary team at SingHealth to develop the brachytherapy device BrachySil® for PsiOncology and subsequently concluded the first-in-man study for the device in 2005. The device is now licenced to OncoSil. Experimental Medicine Director of the Dept of Experimental Surgery at the Singapore General Hospital (2001 – 7), which In 2006 became the first facility in Singapore to be granted full AAALAC accreditation. SEMC is currently the SingHealth Experimental Medicine Center. Medical Education As Inaugural course director conceptualized and led the multi-disciplinary team that developed the Normal Body Course at the Duke-NUS Graduate Medical School, Singapore in 2007.
This prospective genomic-immunomic-clinical study defines the impact of intra-tumoral genomic heterogeneity and the immune micro-environment on the clinical trajectory of a multi-center and multi-national cohort of patients who have undergone surgical resection for liver cancer. The aim is to uncover therapeutic targets, stratify risks and bring Precision Medicine to patients with Liver Cancer through comparing originally resected and recurrent tumour at the level of the genomics and the immune micro environment
- Director of the Academic Multi-disciplinary Liver Cancer Clinic - manage new and follow-up surgical oncology patients at the multi-disicplinary Liver oncology clinic. - participate in multi-disciplinary tumour boards and help co-manage patients in a multi-disciplinary setting - both lead and collaborate in translational research and clinical trials - co-chair the Liver Cancer Service line
- Conceptualise, secure funding and assemble the multi-disciplinary teams required for translational and clinical research to develop more efficacious therapy especially for liver cancer. - Develop and lead multi-institutional and multi-national collaborations. - Direct multi-center clinical trials as protocol chair - Leads multi-disciplinary health sevices outcomes research in liver cancer - mentors junior clinician-scientists